Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 51Urinary Bladder Neoplasms 15Breast Neoplasms 10Carcinoma, Renal Cell 8Colorectal Neoplasms 7Neoplasms 6Lung Neoplasms 6Pancreatic Neoplasms 5Ovarian Neoplasms 5Carcinoma, Transitional Cell 5Carcinoma, Non-Small-Cell Lung 4Motor Activity 3Colonic Neoplasms 3Urologic Neoplasms 2Urologic Diseases 2Ureteral Neoplasms 2Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Small Cell Lung Carcinoma 2Recurrence 2Rectal Neoplasms 2Prostate Cancer Metastatic 2Neoplasms by Site 2Neoplasm Metastasis 2Melanoma 2Kidney Neoplasms 2Kidney Failure, Chronic 2Esophageal Neoplasms 2COVID-19 2Breast Neoplasms, Male 2

Interventions

Abiraterone Acetate 7enzalutamide 6olaparib 5Prednisone 5Pluvicto 5Docetaxel 5radium Ra 223 dichloride 4darolutamide 4cabazitaxel 3Prednisolone 3testosterone 17 beta-cypionate 2fludarabine 2abiraterone 2Nivolumab 2Cyclophosphamide 2Androgen Antagonists 2sipuleucel-T 1rucaparib 1poly ICLC 1pamiparib 1niraparib 1lactitol 1fludarabine phosphate 1fluciclovine F-18 1enfortumab vedotin 1ebastine 1copanlisib 1cabozantinib 1bempegaldesleukin 1avelumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Castration-resistant Prostate Cancer × Standard of Care × Genitourinary × Clear all
NCT06401980 2026-03-30

Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Swiss Cancer Institute

Phase 2 Recruiting
162 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡